Sign Out
Apixaban, a Factor Xa inhibitor, is indicated for: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF): Reduce the risk of stroke, systemic embolism, and death in patients with non-valvular atrial fibrillation with one or more risk factors, including patients unsuitable for warfarin. Compared to warfarin, apixaban also results in less bleeding, including cerebral hemorrhage.
Treatment of VTE: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); Prevention of recurrent DVT and PE.
